188 related articles for article (PubMed ID: 11207836)
1. The effect of aging on circulating levels of proinflammatory cytokines during septic shock. Norasept II Study Investigators.
Marik PE; Zaloga GP;
J Am Geriatr Soc; 2001 Jan; 49(1):5-9. PubMed ID: 11207836
[TBL] [Abstract][Full Text] [Related]
2. Hypothermia and cytokines in septic shock. Norasept II Study Investigators. North American study of the safety and efficacy of murine monoclonal antibody to tumor necrosis factor for the treatment of septic shock.
Marik PE; Zaloga GP
Intensive Care Med; 2000 Jun; 26(6):716-21. PubMed ID: 10945388
[TBL] [Abstract][Full Text] [Related]
3. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
[TBL] [Abstract][Full Text] [Related]
4. sTREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock.
Ravetti CG; Moura AD; Vieira ÉL; Pedroso ÊR; Teixeira AL
J Crit Care; 2015 Apr; 30(2):440.e7-13. PubMed ID: 25541104
[TBL] [Abstract][Full Text] [Related]
5. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group.
Goldie AS; Fearon KC; Ross JA; Barclay GR; Jackson RE; Grant IS; Ramsay G; Blyth AS; Howie JC
JAMA; 1995 Jul; 274(2):172-7. PubMed ID: 7596007
[TBL] [Abstract][Full Text] [Related]
6. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia.
de Werra I; Jaccard C; Corradin SB; Chioléro R; Yersin B; Gallati H; Assicot M; Bohuon C; Baumgartner JD; Glauser MP; Heumann D
Crit Care Med; 1997 Apr; 25(4):607-13. PubMed ID: 9142024
[TBL] [Abstract][Full Text] [Related]
7. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma.
Martin C; Boisson C; Haccoun M; Thomachot L; Mege JL
Crit Care Med; 1997 Nov; 25(11):1813-9. PubMed ID: 9366763
[TBL] [Abstract][Full Text] [Related]
8. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
Fisher CJ; Opal SM; Dhainaut JF; Stephens S; Zimmerman JL; Nightingale P; Harris SJ; Schein RM; Panacek EA; Vincent JL
Crit Care Med; 1993 Mar; 21(3):318-27. PubMed ID: 8440099
[TBL] [Abstract][Full Text] [Related]
9. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
Cohen J; Carlet J
Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
[TBL] [Abstract][Full Text] [Related]
10. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1, -6 and tumor necrosis factor-alpha release is down-regulated in whole blood from septic patients.
Kremer JP; Jarrar D; Steckholzer U; Ertel W
Acta Haematol; 1996; 95(3-4):268-73. PubMed ID: 8677754
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis.
Riché FC; Cholley BP; Panis YH; Laisné MJ; Briard CG; Graulet AM; Guéris JL; Valleur PD
Crit Care Med; 2000 Feb; 28(2):433-7. PubMed ID: 10708179
[TBL] [Abstract][Full Text] [Related]
13. Does N-acetyl-L-cysteine influence cytokine response during early human septic shock?
Spapen H; Zhang H; Demanet C; Vleminckx W; Vincent JL; Huyghens L
Chest; 1998 Jun; 113(6):1616-24. PubMed ID: 9631802
[TBL] [Abstract][Full Text] [Related]
14. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
[TBL] [Abstract][Full Text] [Related]
15. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group.
Calandra T; Gerain J; Heumann D; Baumgartner JD; Glauser MP
Am J Med; 1991 Jul; 91(1):23-9. PubMed ID: 1907101
[TBL] [Abstract][Full Text] [Related]
16. [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis].
Tang S; Xiao H; Fan Y; Wu F; Zhang Z; Li H; Yang Y
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):325-9. PubMed ID: 12126553
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
[TBL] [Abstract][Full Text] [Related]
18. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study.
Zeni F; Pain P; Vindimian M; Gay JP; Gery P; Bertrand M; Page Y; Page D; Vermesch R; Bertrand JC
Crit Care Med; 1996 Feb; 24(2):207-14. PubMed ID: 8605790
[TBL] [Abstract][Full Text] [Related]
19. Two types of septic shock classified by the plasma levels of cytokines and endotoxin.
Endo S; Inada K; Inoue Y; Kuwata Y; Suzuki M; Yamashita H; Hoshi S; Yoshida M
Circ Shock; 1992 Dec; 38(4):264-74. PubMed ID: 1292890
[TBL] [Abstract][Full Text] [Related]
20. The value of immune modulating parameters in predicting the progression from peritonitis to septic shock.
Katja B; Hartmut K; Pawel M; Stefan B; Kox WJ; Spies CD
Shock; 2001 Feb; 15(2):95-100. PubMed ID: 11220648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
